Table 2.
Univariable and multivariable Cox proportional hazards modeling of clinical variables and relative clonality change from baseline to post-treatment with overall survival
| Univariable analysis | Multivariable analysis | |||||
|---|---|---|---|---|---|---|
| HRa | 95% CIb | p | HRa | 95% CIb | p | |
| Male sex | 1.56 | (0.79, 3.08) | 0.197 | 2.14 | (0.79,5.75) | 0.134 |
| Age ≥ 65 years | 1.71 | (0.87, 3.34) | 0.119 | 2.06 | (0.76,5.55) | 0.154 |
| Squamous histology | 1.68 | (0.83, 3.39) | 0.147 | |||
| PD-L1 low/negative | 2.01 | (0.99, 4.10) | 0.054 | 1.94 | (0.74,5.11) | 0.178 |
| ECOG score of 1 at baseline | 2.34 | (1.09, 4.99) | 0.028 | |||
| Ever-smoker | 0.44 | (0.17, 1.15) | 0.093 | 2.65 | (0.66,10.63) | 0.169 |
| Prior line of therapy | 2.09 | (0.91,4.80) | 0.081 | 0.45 | (0.16,1.25) | 0.124 |
| Liver metastases at baseline | 1.94 | (0.95, 3.99) | 0.070 | |||
| Baseline clonality | 6.21 | (0.25,156.03) | 0.267 | |||
| Increased clonalityc | 3.32 | (1.20, 9.20) | 0.021 | 2.79 | (0.90,8.66) | 0.075 |
aHR: hazard ratio
b95% CI: 95% confidence interval
cIncreased clonality: defined based on clonality at day 15 is greater than baseline clonality